H.C. Wainwright keeps USD 5 target for Sarepta Therapeutics stock

Published on 10/20/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 401.25 million, down 34.3 percent year over year. Sarepta Therapeutics stock trades at EUR 15.75 on October 20, 2026.

Analysts weigh pipeline evidence

H.C. Wainwright reiterated a Sell rating and a USD 5.00 target on October 19, 2026.
Second-quarter 2026 revenue was USD 401.25 million, down 34.3 percent year over year.
Sarepta Therapeutics stock was trading at EUR 15.75 at 2:34 p.m. CEST at Lang & Schwarz on October 20, 2026.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics (ISIN US8036071004) was trading at EUR 15.75 at Lang & Schwarz on October 20, 2026, at 2:34 p.m. CEST. The latest analyst call came from H.C. Wainwright, which reiterated a Sell rating and a USD 5.00 price target on October 19, 2026, according to Investing.com.

Three recent dated markers

Sarepta reported new preclinical SRP-1003 data on October 14, 2026. The company said the program produced 80 percent knockdown of pathogenic DMPK RNA in patient-derived muscle cells, according to its Sarepta Therapeutics press-release page.

On October 15, 2026, Leerink Partners reiterated a Hold rating with a USD 20.00 target, as reported by Markets Insider. H.C. Wainwright's October 19 call was the most recent of the three markers.

What does the USD 5 target imply?

The bearish view contrasts with Sarepta's second-quarter 2026 operating picture. Revenue was USD 401.25 million, compared with USD 611.09 million in the year-earlier quarter, while GAAP net loss was USD 4.89 million, according to Markets Insider. The 34.3 percent revenue decline and the loss help explain why analyst views remain divided even after adjusted earnings per share reached USD 0.64 in the quarter.

MarketBeat reported on October 13, 2026, that 21 firms had a consensus Reduce rating and an average 12-month target of USD 22.59. That spread places the current debate on two separate questions: whether ELEVIDYS demand can stabilize and whether the siRNA pipeline can create a second growth engine.

The euro quote at Lang & Schwarz

Sarepta Therapeutics was trading at EUR 15.75 at Lang & Schwarz on October 20, 2026, at 2:34 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Sarepta Therapeutics stock.